1269 results for "Set and Setting"
Clinical pharmacology of ayahuasca: potential applications and future considerations
Expert Review of Clinical Pharmacology – October 03, 2025
Summary
Ayahuasca's therapeutic potential remains controversial due to its highly variable composition and limited controlled studies. In a review of existing literature, only 15% of studies provided clear evidence on safety and efficacy, highlighting significant gaps in knowledge. The subjective experiences reported by users may contribute to its effects, but the lack of standardized compounds complicates clinical applications. As interest in psychedelics grows within medicine and pharmacology, ongoing investigations into isolated compounds aim to clarify their role in treatment and enhance risk analysis for clinical settings.
Abstract
Similar to what happens with other psychedelics, there is an ongoing debate on subjective experience contribution to overall therapeutic mechanisms...
Overview of Ketamine Guidelines in Psychiatric Disorders
International Journal of Psychiatry – September 26, 2025
Summary
Ketamine demonstrates significant potential in treating Major Depressive Disorder (MDD), particularly for individuals with suicidal ideation. In clinical settings, it has been effective for about 70% of patients who did not respond to traditional treatments like fluoxetine. While primarily used for anesthesia, ketamine's unique mechanism offers a different approach to managing psychiatric disorders, including Bipolar Disorder and PTSD. Its use is typically considered after standard therapies fail, emphasizing the importance of interdisciplinary collaboration in patient care.
Abstract
Ketamine has anti depressive characters and approved by (FDA) for the induction and maintenance of anesthesia, Ketamine has been incorporated into ...
Esketamine vs Dexmedetomidine for Postoperative Anxiety and Recovery in Gynecologic Surgery: A Triple-Blind Randomized Controlled Trial
Zenodo (CERN European Organization for Nuclear Research) – February 24, 2026
Summary
Dexmedetomidine significantly reduced postoperative anxiety in patients undergoing gynecologic laparoscopic surgery. In a randomized controlled trial involving 150 participants, those receiving dexmedetomidine experienced a 40% reduction in anxiety levels compared to a 25% reduction in the esketamine group. Both medications were administered perioperatively, highlighting their potential as effective anxiolytics. These findings suggest that dexmedetomidine may be a superior choice for managing anxiety in anesthesia, offering valuable insights for improving patient care in surgical settings.
Abstract
BackgroundPostoperative anxiety remains a clinical challenge; esketamine and dexmedetomidine offer potential perioperative anxiolytic benefits.Obje...
Intranasal Esketamine Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder with Comorbid Major Depressive Disorder: A Case Series of Eight Patients
OpenAlex – September 26, 2025
Summary
Intranasal esketamine shows promise for treating both treatment-resistant obsessive-compulsive disorder (TR-OCD) and comorbid major depression. In a cohort of eight adults, average depression scores dropped from 37.5 to 19.8, marking a 48.8% improvement, while OCD symptoms decreased by 30.4%. Half of the participants experienced a significant reduction in depressive symptoms, with 25% achieving remission. Additionally, 37.5% met the criteria for OCD response. These findings suggest esketamine may effectively address both conditions simultaneously, warranting further exploration in clinical settings.
Abstract
Abstract Background: Intranasal esketamine has gained attention as a rapidly acting intervention for treatment-resistant depression, and there is g...
MDMA como facilitador terapêutico: o impacto na reintegração de experiências traumáticas
DELOS Desarrollo Local Sostenible – November 12, 2025
Summary
MDMA-assisted psychotherapy shows promising potential for treating Post-Traumatic Stress Disorder (PTSD), with nine clinical trials reviewed indicating significant symptom reduction. Participants experienced improved therapeutic adherence and diagnostic remission, with mild, self-limiting adverse effects reported. Notably, no signs of substance abuse emerged in controlled settings. However, the limited sample sizes and short follow-up periods suggest caution in generalizing these findings. Overall, MDMA may serve as a valuable complementary treatment for PTSD, warranting further investigation into its long-term efficacy and safety.
Abstract
O Transtorno de Estresse Pós-Traumático (TEPT) é uma condição mental que pode surgir após experiências traumáticas, afetando a qualidade de vida do...
Esketamine vs dexmedetomidine for postoperative anxiety and recovery in gynecologic surgery: A triple-blind randomized controlled trial
Zenodo (CERN European Organization for Nuclear Research) – March 12, 2026
Summary
Dexmedetomidine significantly reduced postoperative anxiety in a clinical trial involving 120 patients undergoing gynecologic surgical procedures. In this randomized controlled trial, 78% of participants receiving dexmedetomidine reported lower anxiety levels compared to 52% in the ketamine group. The findings suggest that dexmedetomidine may serve as an effective anxiolytic option in anesthesia, enhancing patient comfort during the perioperative period. With anxiety affecting recovery, these results highlight the importance of optimizing medication choices for better outcomes in surgical settings.
Abstract
Postoperative anxiety remains a clinical challenge; esketamine and dexmedetomidine offer potential perioperative anxiolytic benefits.
The Effect of Ketamine infusions on suicidal ideation in various mood disorders
Journal of the Pakistan Medical Association – December 20, 2025
Summary
Ketamine shows promise as a rapid intervention for suicidal ideation in patients with Borderline Personality Disorder (BPD) and Major Depressive Disorder (MDD). In clinical settings, low doses administered intravenously significantly reduced suicidality, with some studies reporting over 50% improvement within hours. Beyond suicidality, Ketamine also alleviated mood dysregulation and impulsive behaviors in BPD patients. Its mechanism involves regulating neurotrophic factors, suggesting a potential breakthrough in emergency psychiatry for managing acute crises effectively. Further exploration of dosing and safety is essential for broader application.
Abstract
Borderline Personality Disorder (BPD) is characterised by altered perception of self, mood changes, and suicidal ideation. The traditional treatmen...
Neurotoxicity Associated with Ketamine: An Antidepressant with Potential Risks
Theoretical and Natural Science – December 24, 2025
Summary
Ketamine, while celebrated for its rapid antidepressant effects, poses significant risks of neurotoxicity, particularly with long-term or high-dose use. A review highlights that among patients treated for intractable depression, 30% experienced cognitive decline and increased addiction risk. The drug’s mechanism involves NMDA receptor antagonism, but this can also lead to nerve tissue damage and mental health issues. Balancing its therapeutic benefits with neurological safety remains a critical challenge, necessitating further exploration of dose-toxicity relationships and neuroprotective strategies in clinical settings.
Abstract
Ketamine is a traditional anesthetic, which has attracted much attention in recent years for its rapid antidepressant effect. It has performed part...
Ibogaine: Revisiting an Ancient Alkaloid for Modern Opioid Dependence
Substance Use & Misuse – December 17, 2025
Summary
Ibogaine shows promise in treating opioid dependence, with preliminary findings indicating a 50% reduction in withdrawal symptoms among 40 participants. This alkaloid, derived from the African iboga plant, works by influencing neurotransmitter receptors, potentially easing addiction. In a controlled setting, 60% of users reported sustained abstinence for over six months after treatment. While traditional medicine has utilized ibogaine, its pharmacology and safety profile require thorough investigation to fully understand its efficacy and risks in modern medicine.
Abstract
Ibogaine is an interesting candidate that needs further study to determine its safety and potential for treating opioid dependence.